The decision, in essence, recognises the potential medical properties of cannabis and paves the way for the relaxing of cannabis classifications in large markets across the world.
() () (FRA:1X8) is ready to capitalise on a number of near-term opportunities that will materialise after the United Nations Commission on Narcotic Drugs’ landmark decision to reclassify cannabis as a Schedule 1 substance, which is the least restrictive drug classification.
The company said the decision to withdraw cannabis from the most dangerous and addictive drugs Schedule IV classification of the 1961 Drug Convention Treaty, signalled a significant global trend toward the relaxation of access to cannabis.
This decision, in essence, recognises the potential medical properties of cannabis and paves the way for the relaxing of cannabis classifications in large markets across the world.
Landmark decision
Creso Pharma co-founder and director Boaz Wachtel said: “The UN ruling to reclassify cannabis is a landmark decision and paves the way for the relaxing of cannabis drug classifications in large markets across the world.
“The result of this vote follows 60 years of status quo, three years of scientific review by the world’s leading health organisations, two years of diplomatic discussions and considerable lobbying from NGOs.
“I am proud and privileged to have been a part of…
